
HEDGEYE

Federal 2020 Spending

In Memoriam: ACA Taxes; NIH Wall of Money and relief for Labs

December 23, 2019



Hedgeye Health Care

Tom Tobin, Managing Director, Health Care

@HedgeyeHC

Ttobin@Hedgeye.com

Emily Evans, Managing Director, Health Policy

@HedgeyeEEvans

Eevans@Hedgeye.com

William McMahon, Analyst, Health Care

© Hedgeye Risk Management LLC.

Legal

DISCLAIMER

Hedgeye Risk Management, LLC ("Hedgeye") is a registered investment advisor, registered with the State of Connecticut. Hedgeye is not a broker dealer and does not provide investment advice to individuals. This research does not constitute an offer to sell, or a solicitation of an offer to buy any security or investment vehicle. This research is presented without regard for individual investment preferences or risk parameters; it is general information and does not constitute specific investment advice, nor does it constitute or contain any legal or tax opinions. This presentation is based on information from sources believed to be reliable. Hedgeye is not responsible for errors, inaccuracies or omissions of information. The opinions and conclusions contained in this report are those of the individual expressing those opinions or conclusion and are intended solely for the use of Hedgeye's clients and subscribers, and the authorized recipients of the content. In reaching its own opinions and conclusions, Hedgeye and its employees have relied upon research conducted by Hedgeye's employees, which is based upon sources considered credible and reliable within the industry. Neither Hedgeye, nor its employees nor any individual expressing opinions, conclusions or data are responsible for the validity or authenticity of the information upon which it has relied.

TERMS OF USE

This report is protected by United States and foreign copyright laws and is intended solely for the use of its authorized recipient. Access must be provided directly by Hedgeye. There is a fee associated with access to this report and the information and materials presented during the event. Redistribution or republication of this report and its contents are strictly prohibited. By joining this call or possessing these materials, you agree to these Terms. For more detail please refer to the appropriate sections of the Hedgeye Services Agreement and the Terms of Service at https://www.hedgeye.com/terms_of_service.



Please submit questions* to

qa@hedgeye.com

^{*}Answered at the end of the call

Health Care Position Monitor



For Week of December 23, 2019

Pri		Price	Mkt Cap (\$B)	Trend	Tail	Best Ideas SHORT	s - Shorts	Price	Mkt Cap (\$B)	Trend	Tail
						Active Sh	orts				
2	\$	25.91	\$2.28	3 √		NVTA	Invitae Corp.	\$ 17.6	9 \$1.76	3 ×	
3	\$	35.53	\$3.7E	3 √	_===	HQY	HealthEquity Inc	\$ 67.4	3 \$4.86	3 ×	
6	9	61.10	\$2.9E	3 √		DXCM	DexCom, Inc.	\$ 224.7	6 \$20.5E	×	
28	\$	285.27	\$72.38	3 √	- V						
32	9	326.47	\$48.0E	3 √							
73	5	73.98	\$6.9E	3 √							
148	\$	148.53	\$30.66	√ √							
						Short Bias	s				
8	\$	80.03	\$5.8E	3		MYGN	Myriad Genetics, Inc.	\$ 25.6	1 \$1.9	3	
6	\$	63.41	\$1.3E	3		EXAS	Exact Sciences Corporation	\$ 86.2	4 \$12.7E	3	
14	\$	14.43	\$0.7E	3		UNH	UnitedHealth Group Incorporated	\$ 280.1	\$265.5	3	
14	9	144.71	\$11.6E	3		DVA	DaVita Inc.	\$ 72.7	0 \$9.46	3	
14	\$	144.61	\$49.0E	3							
6 14 14	9	63.41 14.43 144.71	\$1.3E \$0.7E \$11.6E	3 3		MYGN EXAS UNH	Myriad Genetics, Inc. Exact Sciences Corporation UnitedHealth Group Incorporated	\$ 28	6.2 0.19	6.24 \$12.7E 0.19 \$265.5E	6.24 \$12.7B 0.19 \$265.5B


Disclaimer


Hedgeye's "bias" represents Hedgeye's outlook on companies currently under Hedgeye's review, or for which timing is not right for greater coverage. Hedgeye may or may not provide further commentary on any or all companies represented on the bench and representation of a company on the bench does not forecast whether Hedgeye will or will not issue any additional material on that company.

ACA Tax Collections



On net, worse than CBO projected due to Congressional action





(5,000)

Medical Loss Ratio Calculation Under ACA



Medical Claims + Quality Improvement Expenditures **MLR** Earned Premiums - Taxes, Licensing & Regulatory Fees Earned Premiums Taxes, Licensing & Regulatory Fees **MLR** Earned Premiums Taxes, Licensing & Regulatory Fees **MLR**

ANTM MLR Calculation




MLR impact of repeal of HIF based on 2018 reported numbers

	Scenario I	Scenario II	Scenario III	Scenario IV
Medical Claims	71,895	71,895	71,895	71,895
Quality Improvement				
Activities	250	250	1,750	250
Premiums Earned	85,421	85,421	85,421	83,921
Taxes	1,500	_	_	_
MLR	83.0%	84.5%	86.2%	86.0%

UNH Related Party Transactions




Does MLR burn go in reverse?



The NIH Wall of Money




FY2020 appropriations increase available funding over 7% YoY



The NIH Wall of Money

HEDGEYE


Primary beneficiaries are NCI, NIAID, NIA



PAMA Delay



(Most) Affect Tests by difference between 2017 CLFS Rate and PAMA Calculated Rate



Data Source: CMS, Hedgeye © Hedgeye Risk Management LLC.